Impact ledger
Otsuka Holdings Co., Ltd. (ADR) (OTIC): the developments shaping its investment case
Follow the evidence affecting Otsuka Holdings Co., Ltd. (ADR). Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Otsuka Holdings Co., Ltd. (ADR) · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-19
Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
Channel: Increased competitive pressure and potential market share erosion for their long-acting injectable antipsychotics (e.g., Abilify Maintena) due to UZEDY's demonstrated superior outcomes and cost profile.
Bearish· 3-12m
2026-09-19 · 2 reports
Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
Channel: Potential competitive pressure on Otsuka's long-acting injectable antipsychotics (e.g., Abilify Maintena) due to UZEDY's demonstrated superiority in real-world adherence and cost-effectiveness.
Bearish· 1-3m
2026-09-19
Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
Channel: Increased competitive pressure on long-acting injectable antipsychotics, potentially impacting sales of their similar products.
Bearish· 1-3m
Event impact log
5 events mapped to OTIC since 2026-09-19. Evidence through 2026-09-19.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | Potential competitive pressure on Otsuka's long-acting injectable antipsychotics (e.g., Abilify Maintena) due to UZEDY's demonstrated superiority in real-world adherence and cost-effectiveness. | Bearish | 1-3m | 0.30 |
| 2026-09-19 | Teva real-world data demonstrates UZEDY reduces emergency care and medical costs | Increased competitive pressure on Otsuka's long-acting injectable schizophrenia treatments (e.g., Abilify Maintena) due to Teva's UZEDY demonstrating superior real-world outcomes and cost-effectiveness, potentially leading to slower growth or market share erosion. | Bearish | 3-12m | 0.30 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity | Increased competitive pressure on long-acting injectable antipsychotics, potentially impacting market share and pricing. | Bearish | 3-12m | 0.30 |
| 2026-09-19 | Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions | Increased competitive pressure and potential market share erosion for their long-acting injectable antipsychotics (e.g., Abilify Maintena) due to UZEDY's demonstrated superior outcomes and cost profile. | Bearish | 3-12m | 0.40 |
| 2026-09-19 | Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables | Increased competitive pressure on long-acting injectable antipsychotics, potentially impacting sales of their similar products. | Bearish | 1-3m | 0.30 |
Continue this research
Build your Otsuka Holdings Co., Ltd. (ADR) investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the OTIC entity page →